Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.51 |
| ▸ | MMP12 | P39900 | 6/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | MGAT1 | P26572 | 1/20 | 0.41 |
| ▸ | MGAT3 | Q09327 | 1/20 | 0.41 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100587 | 1.00 | MMP13 (0.51) | MMP13MMP12MMP2ADAMTS5ADAMTS4 | |
| SCHEMBL6210006 | 1.00 | MMP13 (0.51) | MMP13MMP12MMP2ADAMTS5ADAMTS4 | |
| SCHEMBL1099762 | 0.76 | ALDH1A1 (0.48) | MMP13PGRMGAT1MGAT3MGAT2 | |
| SCHEMBL1099764 | 0.76 | ALDH1A1 (0.48) | MMP13PGRMGAT1MGAT3MGAT2 | |
| SCHEMBL6208964 | 0.74 | PGR (0.41) | MMP13MMP2MMP3PGRMGAT1 | |
| SCHEMBL6210997 | 0.74 | ADAM17 (0.43) | MMP13MMP12ADAMTS4MMP14 | |
| SCHEMBL1100647 | 0.74 | HPGD (0.58) | MMP2ADAMTS5PGRSMN1; SMN2NPSR1 | |
| SCHEMBL6727429 | 0.73 | MMP13 (0.44) | MMP13MMP12MMP2MMP3PGR | |
| SCHEMBL6210085 | 0.70 | ADAM17 (0.70) | MMP13MMP2 | |
| SCHEMBL942365 | 0.70 | MMP13 (0.45) | MMP13MMP12MMP2ADAMTS5ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| EP-1370537-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MMP13 6/4885MMP12 2/4885MMP2 9/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MMP13 6/4885MMP12 2/4885MMP2 9/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | MMP13 7/4885MMP12 6/4885MMP2 8/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MMP13 19/4885MMP12 1/4885MMP2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.